Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 3/20 | 0.62 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.62 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.57 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.57 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.57 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | POLA1 | P09884 | 1/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.41 |
| ▸ | DUT | P33316 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10265714 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL10159392 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL19537371 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL19534525 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL12621455 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL12658368 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL23880678 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL12939575 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL14853791 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL16169491 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 714 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12083185-B2 | Small polymeric carriers for delivery of agents | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2024-09-10 | — | — | US | claimed |
| US-20240226335-A9 | RNA Containing Modified Nucleosides and Methods of Use Thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2024-07-11 | — | — | US | claimed |
| US-20240131194-A1 | RNA Containing Modified Nucleosides and Methods of Use Thereof | UNIV PENNSYLVANIA (US) | 2024-04-25 | — | — | US | claimed |
| WO-2021224646-A1 | METHOD FOR THE TREATMENT OF RNA VIRUS INVOLVED DISEASES | TURNSOLE BIOLOGICS LLC. (HU) | 2021-11-11 | — | — | WO | claimed |
| US-20210330808-A1 | SMALL POLYMERIC CARRIERS FOR DELIVERY OF AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-28 | — | — | US | claimed |
| EP-3863609-A1 | SMALL POLYMERIC CARRIERS FOR DELIVERY OF AGENTS | University of Pittsburgh - Of the Commonwealth System of Higher Education (US) | 2021-08-18 | — | — | EP | claimed |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | claimed |
| CN-112823000-A | Small polymer carriers for agent delivery | 联邦高等教育系统匹兹堡大学 | 2021-05-18 | — | — | CN | claimed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | claimed |
| CN-111317739-A | Application of erythromycin estolate in preparation of medicine for specifically inhibiting virus infection | 复旦大学 | 2020-06-23 | — | — | CN | claimed |
| WO-2013159103-A1 | PROGRAMMING AND REPROGRAMMING OF CELLS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2013-10-24 | — | — | WO | claimed |
| WO-2013106344-A1 | 2 '-C-METHYL NUCLEOSIDES CONTAINING A CYCLIC PHOSPHATE DIESTER OF 1, 3-PROPANEDIOL (2-OXO-[1, 3, 2]-DIOXAPHOSPHORINANE) AT POSITION 5' | LIGAND PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | WO | claimed |
| EP-2432792-A1 | N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL]-L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION | Pharmasset, Inc. (US) | 2012-03-28 | — | — | EP | claimed |
| WO-2010135569-A1 | N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL] -L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION | PHARMASSET, INC. (US) | 2010-11-25 | — | — | WO | claimed |
| US-7598230-B2 | For the treatment of viral infections, microbial infections, and proliferative disorders; contain di- or triphosphate moeity mimetics, such as those containing boron anions | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2009-10-06 | — | — | US | claimed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | claimed |
| EP-1501850-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2005-02-02 | — | — | EP | claimed |
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| WO-2003093290-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2003-11-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | P2RY2 2276/4885P2RY4 1503/4885SLC29A1 38/4885 |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | P2RY2 104/4885P2RY4 46/4885SLC29A1 19/4885 |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | P2RY2 531/4885P2RY4 354/4885SLC29A1 498/4885 |
| US-12083185-B2 | Small polymeric carriers for delivery of agents | CD44, PGF, SLC46A1 | P2RY2 4632/4885P2RY4 4629/4885SLC29A1 552/4885 |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | P2RY2 531/4885P2RY4 354/4885SLC29A1 498/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | P2RY2 104/4885P2RY4 46/4885SLC29A1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.